Multiple immunotherapy agents targeting the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway have demonstrated clinical benefit and are approved for the treatment of patients with locally advanced/metastatic NSCLC [9,10]. Here, PDCD1 is linked to non-small cell lung carcinoma.